Agios Pharmaceuticals, Inc.

NASDAQ:AGIO

Biotechnology

Healthcare
$28.76 +1.50%

+$0.50 today

Market cap
$1.72B
Beta
0.59
P/E (TTM)
-4.7
EPS (TTM)
-$7.19
52W Low $22.24High $46.00

Volume 0.47M

Average 1.11M

Returns on capital

Agios Pharmaceuticals, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-34.6%

avg -27.4%

ROIC

-38.2%

avg -40.3%

ROA

-31.8%

avg -15.7%

Analysis

ROA is currently the strongest return metric at -31.8% versus its period average of -15.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Brian Goff

Chief Executive Officer & DirectorUSD 1.45M5739.00K0.07%

Krishnan Viswanadhan

Chief Strategy & Operations OfficerUSD 931.51K473.00K<0.01%

Sarah Gheuens

Chief Medical Officer and Head of Research & DevelopmentUSD 887.23K4616.27K0.03%

Cecilia Jones

Chief Financial OfficerUSD 791.84K513.00K<0.01%

James William Burns

Chief Legal OfficerUSD 780.51K483.00K<0.01%

Craig Thompson

Co-FounderUSD 50K73——

Lewis Clayton Cantley

Co-FounderUSD 50K77——

Shin-San Su

Co-FounderUSD 50K70——

Tak Wah Mak FRSC

Co-FounderUSD 50K80——

T. J. Washburn

Vice President, Controller & Principal Accounting Officer—44——

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 26, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

40

$4.86M

Net Transaction Value

−$4.86M

Net selling

Most Active

Gheuens Sarah

10 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Oct 26, 26

Gheuens Sarah

Direct

Sell$296.5K
Oct 22, 26

Gheuens Sarah

Direct

Sell$18.8K
Oct 21, 26

Gheuens Sarah

Direct

Sell$55.9K
Aug 4, 26

Gheuens Sarah

Direct

Sell$914.4K
Jul 1, 26

Gheuens Sarah

Direct

Sell$150.5K
Apr 2, 26

Burns James William

Direct

Sell$113.8K
Apr 2, 26

Gheuens Sarah

Direct

Sell$102K
Apr 2, 26

Jones Cecilia

Direct

Sell$109K
Apr 2, 26

Milanova Tsveta

Direct

Sell$113.2K
Apr 2, 26

Viswanadhan Krishnan

Direct

Sell$102.7K

1–10 of 40

Summary

Insiders reported 0 buys worth $0.00 and 40 sells worth $4.86M over the last 12 months. That adds up to net selling of $4.86M. Gheuens Sarah was the most active insider with 10 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A5 analysts
RevenueN/AN/A+56.0%
+72.2% (5yr)6 analysts
Net IncomeN/AN/AN/A
N/A6 analysts
EBITN/AN/AN/A
N/A6 analysts

Analysis

Recent growth has been strongest in Revenue at +56.0% over three years. Forward estimates point to Revenue at +72.2% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Agios Pharmaceuticals, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about AGIO's management, answered from reported figures.

Who manages AGIO?

Agios Pharmaceuticals, Inc. (AGIO) lists 10 active executives. The top listed executive is T. J. Washburn, Vice President, Controller & Principal Accounting Officer.

Are AGIO insiders buying or selling?

Recent insider activity shows net buying of $12.57M.